NCT00005032 - Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

January 31, 2001

Study Completion Date

September 30, 2001

Conditions

Lung Cancer

Interventions

BIOLOGICAL

oblimersen sodium

DRUG

paclitaxel

Trial Locations (11)

Arthur G. James Cancer Hospital - Ohio State University, Columbus

Michiana Hematology/Oncology P.C., South Bend

Division of Hematology/Oncology, Park Ridge

Evanston Northwestern Health Care, Evanston

University of Illinois at Chicago, Chicago

University of Chicago Cancer Research Center, Chicago

Louis A. Weiss Memorial Hospital, Chicago

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

Cancer Care Specialists of Central Illinois, S.C., Decatur

Central Illinois Hematology Oncology Center, Springfield

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER